Corcept Therapeutics Inc (CORT)
57.54
+1.62
(+2.90%)
USD |
NASDAQ |
Nov 22, 16:00
56.79
-0.75
(-1.30%)
After-Hours: 20:00
Corcept Therapeutics Revenue (TTM): 628.56M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 628.56M |
| June 30, 2024 | 569.61M |
| March 31, 2024 | 523.53M |
| December 31, 2023 | 482.38M |
| September 30, 2023 | 450.03M |
| June 30, 2023 | 428.15M |
| March 31, 2023 | 413.82M |
| December 31, 2022 | 401.86M |
| September 30, 2022 | 397.62M |
| June 30, 2022 | 392.03M |
| March 31, 2022 | 380.23M |
| December 31, 2021 | 365.98M |
| September 30, 2021 | 352.89M |
| June 30, 2021 | 343.09M |
| March 31, 2021 | 340.06M |
| December 31, 2020 | 353.87M |
| September 30, 2020 | 356.03M |
| June 30, 2020 | 351.21M |
| March 31, 2020 | 334.90M |
| December 31, 2019 | 306.49M |
| September 30, 2019 | 285.42M |
| June 30, 2019 | 268.36M |
| March 31, 2019 | 258.42M |
| December 31, 2018 | 251.25M |
| September 30, 2018 | 237.70M |
| Date | Value |
|---|---|
| June 30, 2018 | 216.01M |
| March 31, 2018 | 189.26M |
| December 31, 2017 | 159.20M |
| September 30, 2017 | 129.73M |
| June 30, 2017 | 108.70M |
| March 31, 2017 | 92.86M |
| December 31, 2016 | 81.32M |
| September 30, 2016 | 72.48M |
| June 30, 2016 | 64.01M |
| March 31, 2016 | 56.24M |
| December 31, 2015 | 50.29M |
| September 30, 2015 | 44.33M |
| June 30, 2015 | 38.35M |
| March 31, 2015 | 32.25M |
| December 31, 2014 | 26.55M |
| September 30, 2014 | 21.65M |
| June 30, 2014 | 17.00M |
| March 31, 2014 | 13.04M |
| December 31, 2013 | 10.36M |
| September 30, 2013 | 7.619M |
| June 30, 2013 | 6.04M |
| March 31, 2013 | 5.024M |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
306.49M
Minimum
Dec 2019
628.56M
Maximum
Sep 2024
408.62M
Average
386.13M
Median
Revenue (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 460.48M |
| Madrigal Pharmaceuticals Inc | -- |
| ADMA Biologics Inc | 382.81M |
| Alnylam Pharmaceuticals Inc | 2.095B |
| Merit Medical Systems Inc | 1.326B |